We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bristol-Myers Squibb (BMY – Research Report) ...

In the company’s first insider transaction in nearly a year, Hirawat bought approximately $100,000 worth of BMY stock on Nov.

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

On Thursday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $58.5 which represents a slight increase of $0.09 or 0.15% from the prior close of $58.41. The stock opened at ...

On Friday, Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $54.14 which represents a decrease of $-0.57 or -1.04% from the prior close of $54.71. The stock opened at $54.7 and ...

BRISTOL-MYERS SQUIBB CO (BMY) is a large-cap stock in the Biotechnology & Drugs industry. The rating using this strategy is 88% based on the firm’s underlying fundamentals and the stock’s ...